group (67% vs. 41%, pϽ0.01). In particular this difference stemmed from an increase of access site-related bleeding (21% vs. 7%, pϽ0.01) and cardiac death (41% vs. 25%, pϽ0.01) in the FF group. The adjusted multivariable regression analysis confirmed radial approach as independent outcome predictor pϭ0.037). Conclusions: Transradial approach use for PCI requiring IABP support positively impacts periprocedural outcome by means of a significant access-site-related bleeding and cardiac death prevention. Thus, its use seems strongly recommended in patients at increased risk of bleeding, such as those admitted for an ACS.
Background: The everolimus-eluting Bioresorbable Vascular Scaffold (Absorb) is a novel approach to treating coronary lesions. A persistent inflammatory response, fibrin deposition and delayed endothelialisation have been reported with overlapping firstgeneration drug eluting stents. We report optical coherence tomography and histological findings in a porcine coronary artery model after implantation of overlapping Absorb or second-generation everolimus-eluting metallic platform stents (XIENCE V [XV]). Methods: 41 overlapping Absorb and overlapping XV devices (3.0ϫ12 mm) were implanted in the main coronary arteries of 17 non-atherosclerotic pigs with a balloon artery ratio of 1.1:1 (10% over-stretch). Implanted coronary arteries were evaluated by OCT at 28 (Absorb: nϭ11, XV: nϭ 7) and 90 days (Absorb: nϭ11, XV: nϭ 8), with immediate histological evaluation following euthanasia at the same time points. One animal from each time point was evaluated with scanning electron microscopy alone. Results: 1407 cross-sections were analysed by OCT and 148 cross-sections analysed histologically. At 28 days in the overlap, OCT analyses indicated 80.1% of Absorb struts and 99.4% of XV struts to be covered (pϽ0.0001), corresponding to histological observations of struts with cellular coverage of 75.4% and 99.6% respectively (pϽ0.001). Uncovered struts were almost exclusively related to the presence of 'stacked' Absorb struts, i.e. with a direct overlay configuration. At 90 days overlapping Absorb and overlapping XV struts demonstrated Ͼ99% strut coverage by OCT and histology, with no evidence of a significant inflammatory process, and comparable % volume obstructions. Conclusions: In porcine coronary arteries implanted with overlapping Absorb, strut coverage is dependent on the overlay configuration of Absorb struts at 28 days and not at 90 days. The potential clinical implications of increased strut thickness in the management of long lesions & coronary bifurcations may have important clinical (e.g. duration of antiplatelet therapy) and design considerations (e.g. longer devices & the requirement of dedicated bifurcation devices to avoid overlapping the device) for current and future devices with bioresorbable platforms.
TCT-34 ABSORB EXTEND: An Interim Report on the 12-month Clinical Outcomes from the First 250 Patients Enrolled

Antonio Bartorelli 1 1 Associate Professor University of Milan-Centro Cardiologivo Monzino, Milan, Italy
Background: The safety and performance of the Absorb Bioresorbable Vascular Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB trial. Results out to 2 years have been presented in 101 patients from the ABSORB Cohort B trial. At 12 months, the MACE rate was 6.9%, with no scaffold thrombosis reported, which was sustained out to 2 years with a MACE rate of 9.0%. Following this trial, ABSORB EXTEND was initiated as a global continued access study (outside of the US) to expand experience with the Absorb BVS to different geographies. Additionally, patients were treated for longer coronary lesions than those in the ABSORB trial using either longer scaffold lengths or planned overlap of the Absorb BVS. Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study that is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients with lesions Յ 28 mm in length and reference vessel diameter of 2.0 -3.3 mm (as assessed by on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel, is permitted. Results: Interim 12-month data in the first 250 patients enrolled in ABSORB EXTEND will be available for the first time in October 2012 and will provide additional data on the 
